Edwards Lifesciences Corp
F:EWL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Edwards Lifesciences Corp
F:EWL
|
US |
|
K
|
Kinross Gold Corp
XBER:KIN2
|
CA |
|
Bank of Communications Co Ltd
HKEX:3328
|
CN |
|
Country Garden Services Holdings Co Ltd
HKEX:6098
|
CN |
|
Growthpoint Properties Ltd
OTC:GWWTF
|
ZA |
|
China Oilfield Services Ltd
SSE:601808
|
CN |
|
Buckle Inc
NYSE:BKE
|
US |
|
Finward Bancorp
NASDAQ:FNWD
|
US |
|
Getty Realty Corp
NYSE:GTY
|
US |
|
E
|
Elis SA
F:7EL
|
FR |
|
M
|
Mitsubishi UFJ Financial Group Inc
SWB:MFZ
|
JP |
|
T
|
Telefonica SA
OTC:TEFOF
|
ES |
Edwards Lifesciences Corp
Edwards Lifesciences makes medical devices for people with serious heart disease. Its main products are replacement heart valves, including minimally invasive valves that can be delivered through a catheter instead of open-heart surgery, plus monitoring tools used in intensive care and during surgery. The company focuses on conditions where the heart cannot pump or valve properly, so its products help doctors treat patients with structural heart disease and monitor them closely in the hospital. Its main customers are hospitals, heart surgeons, interventional cardiologists, and critical care teams. Edwards makes money by selling implanted devices and hospital equipment through a medical sales force and distributors. Many of its products are used in procedures that are repeated across hospitals, which gives the company a steady stream of demand tied to patient care rather than consumer spending. What makes Edwards different is its narrow focus on heart valves and hemodynamic monitoring. It sits in a specialized part of the medical device market where design, clinical evidence, and training matter a lot because its products are used in high-stakes procedures. That makes the company more like a specialist partner to hospitals than a broad medical supplier.
Edwards Lifesciences makes medical devices for people with serious heart disease. Its main products are replacement heart valves, including minimally invasive valves that can be delivered through a catheter instead of open-heart surgery, plus monitoring tools used in intensive care and during surgery. The company focuses on conditions where the heart cannot pump or valve properly, so its products help doctors treat patients with structural heart disease and monitor them closely in the hospital.
Its main customers are hospitals, heart surgeons, interventional cardiologists, and critical care teams. Edwards makes money by selling implanted devices and hospital equipment through a medical sales force and distributors. Many of its products are used in procedures that are repeated across hospitals, which gives the company a steady stream of demand tied to patient care rather than consumer spending.
What makes Edwards different is its narrow focus on heart valves and hemodynamic monitoring. It sits in a specialized part of the medical device market where design, clinical evidence, and training matter a lot because its products are used in high-stakes procedures. That makes the company more like a specialist partner to hospitals than a broad medical supplier.
Strong quarter: Edwards reported first-quarter sales of $1.65 billion, up 12.7% year over year, with results ahead of expectations across all product groups.
Guidance raised: Management lifted full-year 2026 sales growth guidance to 9% to 11% and adjusted EPS guidance to $2.95 to $3.05 after the strong start to the year.
TAVR momentum: TAVR sales rose 11% to $1.2 billion, helped by broader market growth, long-term clinical evidence for SAPIEN, and some share gains, especially in Europe.
TMTT strength: TMTT sales jumped about 42% to $173 million, with EVOQUE, PASCAL and the newly launched SAPIEN M3 all contributing to growth.
Outlook and evidence: Management said its long-term growth story depends on clinical evidence, new indications and technology upgrades, and reaffirmed confidence in 2027-and-beyond growth.
Returns and costs: Edwards bought back about $520 million of stock in the quarter, kept gross margin guidance at 78% to 79%, and said operating margin should land at the high end of its original range.
Management
Bernard J. Zovighian is a notable executive in the medical technology industry, currently serving as the President and Chief Executive Officer of Edwards Lifesciences Corporation, a prominent company specializing in innovative products for structural heart disease and critical care monitoring. Zovighian took on the role of CEO in May 2023, succeeding Michael A. Mussallem. With a strong background in healthcare and extensive experience in global market operations, Zovighian has been instrumental in driving Edwards Lifesciences' growth and innovation strategies. Before becoming CEO, he served as Edwards' Corporate Vice President and General Manager of the Transcatheter Mitral and Tricuspid Therapies (TMTT) business, where he led significant advancements and expansion in these new therapy areas. Zovighian joined Edwards Lifesciences in 2015, bringing with him a wealth of knowledge from previous leadership positions at Baxter International and Johnson & Johnson. His expertise in strategic operations and passion for improving patient outcomes have been critical in steering Edwards towards its mission of transforming patient care through innovation. Under his leadership, the company continues to focus on addressing unmet clinical needs and enhancing life-saving medical technologies globally.
With a strong background in healthcare and extensive experience in global market operations, Zovighian has been instrumental in driving Edwards Lifesciences' growth and innovation strategies. Before becoming CEO, he served as Edwards' Corporate Vice President and General Manager of the Transcatheter Mitral and Tricuspid Therapies (TMTT) business, where he led significant advancements and expansion in these new therapy areas.
Zovighian joined Edwards Lifesciences in 2015, bringing with him a wealth of knowledge from previous leadership positions at Baxter International and Johnson & Johnson. His expertise in strategic operations and passion for improving patient outcomes have been critical in steering Edwards towards its mission of transforming patient care through innovation. Under his leadership, the company continues to focus on addressing unmet clinical needs and enhancing life-saving medical technologies globally.
Scott B. Ullem is the Chief Financial Officer (CFO) at Edwards Lifesciences Corporation, a prominent company specializing in medical innovations for structural heart disease and critical care monitoring. He joined Edwards Lifesciences in this role, bringing with him extensive experience in corporate finance and strategic planning. Prior to his role at Edwards, Ullem held various leadership positions in both public and privately-held companies. Before joining Edwards, he served as the CFO for Bemis Company, Inc., a multinational supplier of flexible packaging, where he oversaw financial operations and contributed to the company’s strategic direction. Ullem's career also includes significant experience in investment banking, having worked at both Bank of America and Goldman Sachs, where he focused on mergers, acquisitions, and capital market financings. Known for his strategic insight, operational acumen, and leadership in financial management, Scott Ullem plays a crucial role in Edwards Lifesciences' strategic growth and operational efficiency. His educational background includes an MBA from Harvard Business School and an undergraduate degree from Indiana University.
Ullem's career also includes significant experience in investment banking, having worked at both Bank of America and Goldman Sachs, where he focused on mergers, acquisitions, and capital market financings. Known for his strategic insight, operational acumen, and leadership in financial management, Scott Ullem plays a crucial role in Edwards Lifesciences' strategic growth and operational efficiency. His educational background includes an MBA from Harvard Business School and an undergraduate degree from Indiana University.
Donald E. Bobo Jr. is a seasoned executive at Edwards Lifesciences Corp., a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. With an extensive career in the medical technology industry, Mr. Bobo has been instrumental in driving the strategic initiatives and operations at Edwards. He has held various leadership roles within the company, including positions in strategy, corporate development, and product development. Mr. Bobo's expertise spans over three decades, during which he has contributed significantly to the advancement of medical technologies and therapies, particularly focusing on enhancing patient care and outcomes. He is known for his strategic vision and operational acumen, playing a pivotal role in Edwards' growth and innovation in heart valve therapies and critical care technologies. Through his leadership, Donald has helped Edwards maintain its position as a pioneer in the medical field, driving forward its commitment to improving the lives of patients worldwide.
He has held various leadership roles within the company, including positions in strategy, corporate development, and product development. Mr. Bobo's expertise spans over three decades, during which he has contributed significantly to the advancement of medical technologies and therapies, particularly focusing on enhancing patient care and outcomes.
He is known for his strategic vision and operational acumen, playing a pivotal role in Edwards' growth and innovation in heart valve therapies and critical care technologies. Through his leadership, Donald has helped Edwards maintain its position as a pioneer in the medical field, driving forward its commitment to improving the lives of patients worldwide.
Larry L. Wood is a well-regarded figure in the medical technology sector, recognized for his impactful career at Edwards Lifesciences Corporation. He serves as the Corporate Vice President and Group President for Transcatheter Aortic Valve Replacement (TAVR). In this vital leadership role, Wood has been instrumental in advancing Edwards Lifesciences' position as a leader in the development and commercialization of heart valve therapies. Joining Edwards in 1985, Wood brought his extensive knowledge and expertise to various areas within the company, including manufacturing, regulatory affairs, sales, marketing, and clinical development. His long-standing tenure at Edwards has allowed him to significantly contribute to the company's strategic growth and the pioneering of minimally invasive heart valve replacement technologies. Larry Wood's leadership has been particularly pivotal in the global expansion and commercial success of TAVR, which has revolutionized the treatment for patients with severe aortic stenosis who are at high risk for open-heart surgery. Under his guidance, the TAVR business has experienced substantial growth, reflecting his expertise in product development and market entry strategies. As a leader, Wood is known for fostering innovation and collaboration, both within the company and throughout the medical community. His commitment to improving patient outcomes has been a driving force behind Edwards Lifesciences' innovations and its mission to help patients live longer, healthier lives.
Joining Edwards in 1985, Wood brought his extensive knowledge and expertise to various areas within the company, including manufacturing, regulatory affairs, sales, marketing, and clinical development. His long-standing tenure at Edwards has allowed him to significantly contribute to the company's strategic growth and the pioneering of minimally invasive heart valve replacement technologies.
Larry Wood's leadership has been particularly pivotal in the global expansion and commercial success of TAVR, which has revolutionized the treatment for patients with severe aortic stenosis who are at high risk for open-heart surgery. Under his guidance, the TAVR business has experienced substantial growth, reflecting his expertise in product development and market entry strategies.
As a leader, Wood is known for fostering innovation and collaboration, both within the company and throughout the medical community. His commitment to improving patient outcomes has been a driving force behind Edwards Lifesciences' innovations and its mission to help patients live longer, healthier lives.
Dr. Todd J. Brinton is an accomplished medical professional and executive currently serving at Edwards Lifesciences Corporation. He is known for his significant contributions to the field of cardiovascular medicine and medical technology. Dr. Brinton holds the title of Corporate Vice President, Advanced Technology at Edwards Lifesciences. Before joining Edwards Lifesciences, he had an extensive career in academia and entrepreneurship. Dr. Brinton served as a Clinical Professor of Medicine (Cardiology) at Stanford University and was also involved with the Stanford Byers Center for Biodesign as a Senior Fellowship Director. His work in biodesign has been pivotal in training and mentoring the next generation of innovators in medical technology. In addition to his academic roles, Dr. Brinton is recognized for his involvement in the development and commercialization of groundbreaking cardiovascular devices. He has co-founded several medical device companies, which have advanced treatments for patients with heart conditions. Dr. Brinton is a board-certified cardiologist and a Fellow of the American College of Cardiology (FACC), reflecting his expertise and leadership in the field. His multifaceted career highlights a strong commitment to improving patient care through innovation in medical technology.
Before joining Edwards Lifesciences, he had an extensive career in academia and entrepreneurship. Dr. Brinton served as a Clinical Professor of Medicine (Cardiology) at Stanford University and was also involved with the Stanford Byers Center for Biodesign as a Senior Fellowship Director. His work in biodesign has been pivotal in training and mentoring the next generation of innovators in medical technology.
In addition to his academic roles, Dr. Brinton is recognized for his involvement in the development and commercialization of groundbreaking cardiovascular devices. He has co-founded several medical device companies, which have advanced treatments for patients with heart conditions.
Dr. Brinton is a board-certified cardiologist and a Fellow of the American College of Cardiology (FACC), reflecting his expertise and leadership in the field. His multifaceted career highlights a strong commitment to improving patient care through innovation in medical technology.
Arnold A. Pinkston, J.D., is a distinguished legal professional and executive with extensive experience in corporate law and governance. He is known for his role at Edwards Lifesciences Corp., a prominent company specializing in innovative medical technologies designed to treat advanced cardiovascular disease. As of his tenure with Edwards Lifesciences, Arnold Pinkston has served as the General Counsel, where he is responsible for overseeing the company's legal affairs, ensuring compliance with legal and regulatory requirements, and providing guidance on corporate governance issues. His role involves managing a variety of legal functions, from intellectual property matters to mergers and acquisitions, and plays a vital role in supporting Edwards Lifesciences' mission and business strategy. Before joining Edwards Lifesciences, Mr. Pinkston held several high-profile legal roles in other major companies. He has a rich background in handling complex legal challenges in different sectors, which shaped his approach to managing corporate legal frameworks and risk management effectively. His experience includes previous roles as General Counsel for other corporations, where he honed his skills in leading legal teams and advising senior executives. Arnold A. Pinkston's educational background includes a Juris Doctor (J.D.) degree, reflecting his strong foundation in legal expertise and a commitment to maintaining high ethical standards in all of his professional dealings. His leadership and legal insights have been invaluable in guiding Edwards Lifesciences through various business environments and challenges.
As of his tenure with Edwards Lifesciences, Arnold Pinkston has served as the General Counsel, where he is responsible for overseeing the company's legal affairs, ensuring compliance with legal and regulatory requirements, and providing guidance on corporate governance issues. His role involves managing a variety of legal functions, from intellectual property matters to mergers and acquisitions, and plays a vital role in supporting Edwards Lifesciences' mission and business strategy.
Before joining Edwards Lifesciences, Mr. Pinkston held several high-profile legal roles in other major companies. He has a rich background in handling complex legal challenges in different sectors, which shaped his approach to managing corporate legal frameworks and risk management effectively. His experience includes previous roles as General Counsel for other corporations, where he honed his skills in leading legal teams and advising senior executives.
Arnold A. Pinkston's educational background includes a Juris Doctor (J.D.) degree, reflecting his strong foundation in legal expertise and a commitment to maintaining high ethical standards in all of his professional dealings. His leadership and legal insights have been invaluable in guiding Edwards Lifesciences through various business environments and challenges.
Dirksen J. Lehman is the Corporate Vice President of Public Affairs at Edwards Lifesciences Corporation, a leading medical technology company specializing in heart valve therapies and critical care monitoring. In this role, Lehman is responsible for overseeing the company's public affairs activities, which include government affairs, communications, and corporate social responsibility initiatives. Before joining Edwards Lifesciences, Lehman held senior roles in government relations and public affairs, serving in capacities such as a strategist and advisor in political and legislative environments. He has a wealth of experience in navigating complex policy issues and advocating for healthcare advancements. Lehman's leadership in public affairs is instrumental in promoting Edwards Lifesciences' mission to transform patient care and enhance lives globally.
Christine Z. McCauley is recognized for her role as the Corporate Vice President, Human Resources at Edwards Lifesciences Corporation. With a distinguished career at Edwards, she oversees the strategic direction and management of the company's global human resources functions. McCauley focuses on talent management, employee development, and organizational effectiveness, which are critical to Edwards’ mission of providing innovative solutions for people fighting cardiovascular disease. Her leadership plays a vital role in fostering a collaborative and dynamic work environment that supports Edwards' objectives and growth strategies. McCauley brings a wealth of experience in HR and has been instrumental in shaping a diverse and inclusive workplace culture at the company. Her contributions are foundational in aligning the employment brand with the company's innovative spirit and humanitarian focus.
